Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
The Journal of Urology
|
May 16, 2006
A novel microfluidic device for male subfertility screening
Matthew C McCormack, Stewart McCallum, Barry Behr
British Journal of Pharmacology
|
March 28, 2013
Inhibition of ejaculation by the non-peptide oxytocin receptor antagonist GSK557296: a multi-level site of action
Pierre Clément, Jacques Bernabé, Sandrine Compagnie, et al.
The Journal of Urology
|
August 21, 2002
Men with nonobstructive azoospermia have Leydig cell hypertrophy but not hyperplasia
Jennifer A Tash, Stewart McCallum, Matthew P Hardy, et al.
Investigational New Drugs
|
August 25, 2012
Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
Tanguy Seiwert, John Sarantopoulos, Howard Kallender, et al.
The Journal of Urology
|
April 17, 2002
Comparison of intussusception pull-through end-to-side and conventional end-to-side microsurgical vasoepididymostomy: prospective randomized controlled study in male wistar rats
Stewart McCallum, Philip S Li, Yefim Sheynkin, et al.
Plos One
|
July 23, 2014
A randomised trial evaluating the effects of the TRPV1 antagonist SB705498 on pruritus induced by histamine, and cowhage challenge in healthy volunteers
Rachel A Gibson, Jon Robertson, Harshna Mistry, et al.
Clinical Pharmacology in Drug Development
|
January 22, 2020
Platelet Function: Meloxicam Intravenous in Whole Blood Samples From Healthy Volunteers
Jonathan S Jahr, Shawn Searle, Stewart McCallum, et al.
Investigational New Drugs
|
October 12, 2012
A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors
Geoffrey I Shapiro, Stewart McCallum, Laurel M Adams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 18, 2010
A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2
Joseph Paul Eder, Geoffrey I Shapiro, Leonard J Appleman, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
The Journal of Urology
|
May 16, 2006
A novel microfluidic device for male subfertility screening
Matthew C McCormack, Stewart McCallum, Barry Behr
British Journal of Pharmacology
|
March 28, 2013
Inhibition of ejaculation by the non-peptide oxytocin receptor antagonist GSK557296: a multi-level site of action
Pierre Clément, Jacques Bernabé, Sandrine Compagnie, et al.
The Journal of Urology
|
August 21, 2002
Men with nonobstructive azoospermia have Leydig cell hypertrophy but not hyperplasia
Jennifer A Tash, Stewart McCallum, Matthew P Hardy, et al.
Investigational New Drugs
|
August 25, 2012
Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
Tanguy Seiwert, John Sarantopoulos, Howard Kallender, et al.
The Journal of Urology
|
April 17, 2002
Comparison of intussusception pull-through end-to-side and conventional end-to-side microsurgical vasoepididymostomy: prospective randomized controlled study in male wistar rats
Stewart McCallum, Philip S Li, Yefim Sheynkin, et al.
Plos One
|
July 23, 2014
A randomised trial evaluating the effects of the TRPV1 antagonist SB705498 on pruritus induced by histamine, and cowhage challenge in healthy volunteers
Rachel A Gibson, Jon Robertson, Harshna Mistry, et al.
Clinical Pharmacology in Drug Development
|
January 22, 2020
Platelet Function: Meloxicam Intravenous in Whole Blood Samples From Healthy Volunteers
Jonathan S Jahr, Shawn Searle, Stewart McCallum, et al.
Investigational New Drugs
|
October 12, 2012
A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors
Geoffrey I Shapiro, Stewart McCallum, Laurel M Adams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 18, 2010
A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2
Joseph Paul Eder, Geoffrey I Shapiro, Leonard J Appleman, et al.
Page
of 1